All In Biotech

Drug Trial Radar · NCT02492711

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 624 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

624

Actual

Start

Aug 24, 2015

Primary completion

Aug 11, 2021

Study completion Jun 14, 2022

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Jul 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.

Conditions

  • HER-2 Positive Breast Cancer
  • Metastatic Neoplasm

Interventions

  • MargetuximabBiological

    15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,

  • TrastuzumabBiological

    8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle

  • Physician's choice of chemotherapy.Drug

    Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Determined by Independent Radiological Review.Time frame: Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, average 5 months.
  2. Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).Time frame: Throughout the study, average 21 months
  3. Number of Patients With Grade 3 or Higher Infusion Related ReactionsTime frame: 22 days

Locations

167 sites in 18 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Center

    Chandler, Arizona

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Western Regional Medical Center, Inc.

    Goodyear, Arizona

  • East Valley Hematology And Oncology

    Burbank, California

  • UCLA Hematology Oncology Santa Monica

    Los Angeles, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Sharp Memorial Hospital

    San Diego, California

  • University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Kaiser Permenente Medical Center

    Vallejo, California

  • Poudre Valley Health Care, Inc.

    Fort Collins, Colorado

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Florida Cancer Specialists

    New Port Richey, Florida

  • Orlndo Health Cancer Center

    Orlando, Florida

  • Hem-Onc Associates

    Port Saint Lucie, Florida

  • Palm Beach Cancer Center

    West Palm Beach, Florida

  • Piedmont Cancer Institute, P.C.

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers, PC

    Marietta, Georgia

  • CTCA - Southeastern Regional Medical Center

    Newnan, Georgia

  • Kaiser Permanente Hawaii Moanalua Medical Center

    Honolulu, Hawaii

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • CTCA - Midwestern Regional Medical Center

    Zion, Illinois

  • Indiana University Health Goshen Center for Cancer Care

    Goshen, Indiana

  • ARH Cancer Clinic

    Hazard, Kentucky

  • St. Joseph's Hospital

    Lexington, Kentucky

  • Touro Infirmary Hospital

    New Orleans, Louisiana

  • New England Cancer Specialists

    Scarborough, Maine

  • Mercy Medical Center

    Baltimore, Maryland

  • Tufts-NEMC Cancer Center

    Boston, Massachusetts

  • Forrest General Hospital

    Hattiesburg, Mississippi

  • Saint Luke's Cancer Specialists

    Kansas City, Missouri

  • Mercy Hospital Saint Louis

    St Louis, Missouri

  • Dartmouth-Hitchcock - Norris C

    Lebanon, New Hampshire

  • New Jersey Hematology Oncology Associates

    Brick, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Saint Barnabas Medical Center - The Cancer Center

    Livingston, New Jersey

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.